Implementing our guidance can generate cost savings and free up resources and capacity that can be used for other services.
Use our cost saving resource to help you assess how our guidance could benefit you.
Save money with NICE guidance
Our resource impact reports and templates allow you to estimate savings for your local setting more accurately.
The estimated savings below are per 100,000 population and when the full uptake is achieved. The figures can be prorated, based on the total local population. This will give an estimate of the local impact.
We've identified the following NICE guidance that could generate cost savings:
Savings are based on a reduction in waiting times for an abortion, ultrasounds and women having rhesus status testing and anti-D prophylaxis.
Guideline on diverticular disease: diagnosis and management (NG147)
Cash savings are driven by the expected reduction in the number of patents needing stoma care. Capacity savings are made because of an increase in patients who have a CT scan upon admission.
Guideline on high-sensitivity troponin tests for the early rule out of NSTEMI (DG40)
The small cash saving is based on lower test cost. Capacity savings are based on a reduction in the number of people admitted to hospital with suspected non-ST-segment-elevation myocardial infarction.
Cash savings are as a result of reduced use of eye drops following increased routine use of selective laser trabeculoplasty (SLT).
There is also expected to be a small reduction in the number of cataract or intraocular pressure (IOP) lowering surgery procedures. These benefits outweigh the increased costs of increased SLT procedures to leave a small overall net saving.
Guideline on joint replacement (primary): hip, knee and shoulder (NG157)
Cash savings based on a change from total to partial knee replacements. Capacity savings are based on a reduction in revisions.
Medical technologies guidance on KardiaMobile for detecting atrial fibrillation (MTG64)
Cost savings are based on a reduction in repeat diagnostic assessments and the associated cardiology appointments.
Medical technologies guidance on Leukomed Sorbact for preventing surgical site infection (MTG55)
Savings are based on a comparison to standard dressings and are evaluated on anticipated bed day savings.
Guideline on low back pain and sciatica in over 16s: assessment and management (NG59)
Savings come from changes to the pharmacological treatments for people with acute or chronic severe sciatica.
Guideline on renal and ureteric stones: assessment and management (NG118)
Savings result from many areas, including an increase in shockwave lithotrips and a reduction in surgical interventions.
Guideline on thyroid disease: assessment and management (NG145)
Savings come from reduction in the use of antithyroid drugs.
Medical technologies guidance on UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
Potential savings mainly come from better healing with UrgoStart dressings. This would require fewer GP and secondary care appointments. In turn, this may lead to a reduction in amputations.
Guideline on venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
Cash savings result from changes to prescribing budgets in both primary and secondary care. Capacity savings come from a reduction in imaging screening.